Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.952494
Abstract: Background Both apatinib and programmed death 1 (PD-1) monoclonal antibody (mAb) monotherapy have been licensed in China for the third-line treatment of advanced gastric cancer (AGC). However, whether the combination could improve the prognosis of… read more here.
Keywords: apatinib; apatinib plus; monotherapy; plus mab ... See more keywords